Investor Presentaiton slide image

Investor Presentaiton

Coloplast revenue development by geography and total Europe Other Developed Markets 15 9 2 4 6 2 4 5 16 21 12,916 16 10,573 10,820 11,261 8 10,404 6 10 11 3 5 5,775 4,380 4,644 4,785 4,757 18/19 19/20 20/21 21/22 YTD 22/23 18/19 19/20 20/21 21/22 YTD 22/23 FY 21/22 and YTD 22/23 reported growth rates include respectively 8%-pts and 4%-pts impact from the Atos Medical acquisition Emerging Markets FY 21/22 and YTD 22/23 reported growth rates include respectively 6%-pts and 5%-pts impact from the Atos Medical acquisition 15 15 12 12 10 8 10 10 3 8 2,986 3,080 3,380 3,888 3,113 18/19 19/20 20/21 21/22 YTD 22/23 FY 21/22 and YTD 22/23 reported growth rates include 1%-pts impact from the Atos Medical acquisition Revenue (DKKm) 66 Atos Medical part of organic growth since February 1, 2023 Coloplast group 9 4 7 16 11 8 3 5 6 22,579 17,939 18,544 19,426 18,274 18/19 19/20 20/21 21/22 YTD 22/23 FY 21/22 and YTD 22/23 reported growth rates include respectively 6%-pts and 4%-pts impact from the Atos Medical acquisition Reported growth (%) Organic growth (%) Coloplast
View entire presentation